The Borlaug Report #4: Biologics CDMOs

The Secular Shift in How Drugs are Made (Part 2)

Introduction

A couple weeks ago, I wrote about the bioprocessing megatrend and how life science tools companies are benefiting from it. The key takes are below: 

• Large molecule drugs dubbed “biologics” are becoming a higher percent of all drugs in the pharmaceutical R&D pipeline each year.

• These drugs are more complex to make and need specialized types of …